Novartis: presents results for MS drug

(CercleFinance.com) - Novartis will present data to ACTRIMS-ECTRIMS for Kesmimpta (ofatumumab) in newly diagnosed naïfs de traitement adults with recurring multiple sclerosis.


This data still supports Kesmpta as a primary treatment option for adults with RMS.

This encouraging data shows that newly diagnosed untreated patients may benefit from reduced disease activity when treated with Kesimpta, said Dr. Amit Bar-Or, from the University of Pennsylvania.


Copyright (c) 2020 CercleFinance.com. All rights reserved.